CatalogID: 11949 Purity: ≥95% CAS NO.: 196936-04-6

  • CAS No.:
  • Synonyms:
  • Purity:
  • MF:
  • MW:
  • Recommended Storage Condition:
    Store at -5°C,keep in dry and avoid sunlight.
  • Uses:

Amine-PEG36-acid (NH2-PEG36-COOH) is a PEG derivative containing an amino group and a terminal carboxylic acid. The amino groups can react with carboxylic acids, activated NHS esters, carbonyl groups (ketones, aldehydes), etc. Terminal carboxylic acids can react with primary amine groups in the presence of activating agents such as EDC or DCC to form stable amide bonds. Amine-PEG36-acid can be used to develop antibody-drug conjugates (ADC), and it can also acts as PROTAC linker that can be used in the synthesis of PROTACs.

Amino-PEG36-acid has several advantages over similar amino acids used as spacers, such as:

  1. Uniform PEG chain length and molecular weight;
  2. Easy characterization and high purity;
  3. Higher water solubility and increased hydrodynamic volume of the conjugate molecule;
  4. Non-antigenic/non-immunogenic properties;

Biopharma PEG provides high purity monodisperse (discrete) PEG with an extensive variety of functional groups(such as Amine-PEG36-Acid), from grams to kilogram, even tons batch size in both non-GMP and GMP grades. Email at sales@biochempeg.com and start using a superior product for your next product R&D project.

1. Rubio-Garcia J, Coppel Y, Lecante P, Mingotaud C, Chaudret B, Gauffre F, Kahn ML. One-step synthesis of metallic and metal oxide nanoparticles using amino-PEG oligomers as multi-purpose ligands: size and shape control, and quasi-universal solvent dispersibility. Chem Commun (Camb). 2011 Jan 21;47(3):988-90. doi: 10.1039/c0cc02615h. Epub 2010 Nov 26. PubMed PMID: 21113535.
2. Kitagawa F, Kubota K, Sueyoshi K, Otsuka K. One-step preparation of amino-PEG modified poly(methyl methacrylate) microchips for electrophoretic separation of biomolecules. J Pharm Biomed Anal. 2010 Dec 15;53(5):1272-7. doi: 10.1016/j.jpba.2010.07.008. Epub 2010 Aug 1. PubMed PMID: 20678876.
​3. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562